Company / Working Capital
X4 Pharmaceuticals, Inc Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$235.8M
FY2025
5-year range
$71.4M / $235.8M
FY2021-FY2025
Trend
+197.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $106M to $236M over the past 3 years.
Based on SEC 10-K filings.
$236M in FY2025 with a 5-year CAGR of +27.0%.
Improved from $106M to $236M over the past 3 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +30.4%
- 5-Year CAGR
- +27.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +27.0%, indicating consistent growth.
- In FY2025, working capital increased 197.4% year-over-year.
- Lowest working capital in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $235.8M | +197.4% |
| FY2024 | $79.3M | -25.4% |
| FY2022 | $106.4M | +44.0% |
| FY2021 | $73.9M | +3.5% |
| FY2020 | $71.4M | +140.4% |
| FY2018 | $29.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026